Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.

"Declarations Ethical approval and consent to participateThe study was approved by the Institutional Review Board/Institutional Ethics Committee of each study site, and the study was performed according to consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice (GCP), all applicable laws, rules, and regulations. A signed written informed consent form was obtained from each patient before conducting any study-related procedures. Consent for publicationNot applicable. Competing interestsClot PF, Farenc C, Krahnke T, Staudinger H, Suratt BT, Pomponio R, Tardat A, Patel N, Wiekowski M, Lin Y: Sanofi employees, may hold stock and/or stock options in the company. Florian P: Sanofi employee when this work was conducted and holds Sanofi stock; now works for Boehringer Ingelheim Vetmedica GmbH. Terrier B: Received consulting fees from Roche, Chugai, GSK, AstraZeneca, BMS, Terumo BCT, Sanofi, LFB, Grifols. This work was previously presented atEuropean Respiratory Society – 31st Annual Congress (ERS 2021). Competing interests Clot PF, Farenc C, Krahnke T, Staudinger H, Suratt BT, Pomponio R, Tardat A, Patel N, Wiekowski M, Lin Y: Sanofi employees, may hold stock and/or stock options in the company. Florian P: Sanofi employee when this work was conducted and holds Sanofi stock; now works for Boehringer Ingelheim Vetmedica GmbH. Terrier B: Received consulting fees from Roche, Chugai, GSK, AstraZeneca, BMS, Terumo BCT, Sanofi, LFB, Grifols."

"Funding The study was funded by Sanofi. The funder of the study was involved in the study design, data collection, data analysis, data interpretation, and writing of the report."

"ClinicalTrials.gov identifier NCT04469621, first posted on clinicaltrials.gov on July 14, 2020."